12,372 trials
Peanut Allergy · Multi-food Allergy
Primary: Number of Participants by Stage 1 Treatment Assignment, Omalizumab Versus Placebo, Who Successfully Consume a Single Dose of ≥600 mg of Peanut Protein Without…
Neovascular Age Related Macular Degeneration
Primary: Percentage Change in Choroidal Neovascularization (CNV) Lesion Area Measured by Optical Coherence Tomography-Angiograph (OCT-A) From Baseline to Week 12 — -79.29 %…
Hepatic Steatosis · Polycystic Ovarian Syndrome · Obesity
Primary: Hepatic Glucose Release — 1.85; 1.46; 1.54; 1.88 mg/kg/min
Relapsing Multiple Sclerorsis · Multiple Sclerosis, Primary Progressive
Primary: Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab — -1232.97; -1169.13; -1008.13; -931.83 pg/mL
Pain
Primary: Summed Pain Intensity Difference Over 0 to 12 Hours (SPID12) After Time 0 — 51.84; 56.33; 19.11 score on a scale*hours — p=<0.0001
Hypertension · Kidney Diseases
Primary: Change in Estimated Glomerular Filtration Rate
Knee Arthroplasty, Total
Primary: Percentage of Patients Presenting With Pain in the Back of the Knee 6 Hours After Surgery — 21.7; 45.8 percentage of patients reporting pain
Irritability Associated With Autism Spectrum Disorder
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded By Severity, Serious TEAEs and Trial Discontinuation Due to TEAEs — 23; 24; 15; 19…
Influenza Immunization
Primary: Geometric Mean Titers (GMTs) Against Influenza Vaccine Antibodies at Day 29 — 1946; 982; 1975; 604 titer
Gonorrhea
Primary: Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8)…
Pneumococcal Disease
Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) — 32.9; 39.1 Percentage of participants
Vulvar and Vaginal Atrophy
Primary: The Primary Efficacy Endpoint — 49; 59; 52; 63 participants — p=<0.0001
Urinary Tract Infections · Acute Pyelonephritis
Primary: Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population — 207; 83 Participants — p=0.0088
Respiratory Distress Syndrome
Primary: Intubation and Instillation of Liquid Surfactant — 69; 120 Participants
Endometriosis
Primary: Reduction of Dysmenorrhea (DYS) at Month 3 - Proportion of Responders — 44.0; 72.9; 23.5 Percentage of responders — p=<0.001